TWD 572.0
(-1.38%)
Year | Operating Income | Operating Income Growth |
---|---|---|
2023 | - TWD | 48.43% |
2022 | -1.82 Billion TWD | 34.9% |
2021 | -2.8 Billion TWD | -44.4% |
2020 | -1.93 Billion TWD | -128.42% |
2019 | -849.22 Million TWD | 0.0% |
Year | Operating Income | Operating Income Growth |
---|---|---|
2024 Q1 | 339.71 Million TWD | 262.78% |
2024 Q2 | 932.71 Million TWD | 30.27% |
2023 Q2 | -185.45 Million TWD | 74.97% |
2023 Q4 | -208.69 Million TWD | -207.13% |
2023 FY | -940.24 Million TWD | 48.43% |
2023 Q1 | -740.9 Million TWD | -27.84% |
2023 Q3 | 194.79 Million TWD | 205.04% |
2022 Q3 | -564.92 Million TWD | 0.0% |
2022 FY | -1.82 Billion TWD | 34.9% |
2022 Q4 | -579.54 Million TWD | -2.59% |
2021 FY | -2.8 Billion TWD | -44.4% |
2020 FY | -1.93 Billion TWD | -128.42% |
2019 FY | -849.22 Million TWD | 0.0% |
Name | Operating Income | Operating Income Difference |
---|---|---|
Grape King Bio Ltd | 2.49 Billion TWD | 100.0% |
Standard Chem & Pharm CO., LTD. | 1.25 Billion TWD | 100.0% |
Maywufa Company Ltd. | 211.01 Million TWD | 100.0% |
ScinoPharm Taiwan, Ltd. | 314.49 Million TWD | 100.0% |
Lotus Pharmaceutical Co., Ltd. | 4.9 Billion TWD | 100.0% |
LIWANLI Innovation Co., Ltd. | - TWD | NaN% |
YungShin Global Holding Corporation | 929.61 Million TWD | 100.0% |
PhytoHealth Corporation | -121.67 Million TWD | 100.0% |
SCI Pharmtech, Inc. | 160.3 Million TWD | 100.0% |
Formosa Laboratories, Inc. | 674.97 Million TWD | 100.0% |
Bora Pharmaceuticals Co., LTD. | 5.24 Billion TWD | 100.0% |